Literature DB >> 345345

Autoimmune hemolytic anemia and cold hemagglutinin disease: clinical disease and laboratory findings.

P D Issitt.   

Abstract

As is apparent from the length of this review, a multitude of laboratory investigations can be performed on the blood of patients with AIHA and CHD. Unfortunately, because of the considerable complexity of some of these tests, their significance is not always apparent to the physician who treats the patient. Communication gaps between the laboratory scientist and the physician at the bedside are bound to occur because of the high degree of specialization of both immunohematology and medical care. The purpose of this review has been to bridge the communication gap. The agents that cause AIHA and CHD are antibodies. Although they are often autoantibodies of complex specificity, usually reacting with all normal red cells, they nevertheless obey most of the rules explaining the action of alloantibodies that sometimes complicate transfusion therapy. By approaching AIHA and CHD as antibody-induced conditions, and by regarding autoantibodies as similar in their actions to alloantibodies, hopefully, physicians will appreciate the significance of the tests performed in the laboratory. For their part, the laboratory workers will be able not only to report test results but also to explain the findings. This review may aid in establishing the essential dialogue.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 345345

Source DB:  PubMed          Journal:  Prog Clin Pathol        ISSN: 0079-6174


  2 in total

1.  Autoimmune haemolytic anaemia: recent advances in pathogenesis, diagnosis and treatment.

Authors:  A Poschmann; K Fischer
Journal:  Eur J Pediatr       Date:  1985-03       Impact factor: 3.183

2.  Severe autoimmune hemolytic anemia with cold agglutinin and sclerodermic features--favorable response to danazol.

Authors:  G Lugassy; T Reitblatt; A Ducach; S Oren
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.